Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
NCT04043195 is a phase 1/2 interventional trial sponsored by Hatim Husain. As of 21 Nov 2026, it is active and no longer recruiting. It studies Ipilimumab, Nivolumab and Oxaliplatin in Advanced NSCLC. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 14 Aug 2019 and a primary completion date of 31 Dec 2025.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04043195 |
| Status | Active not recruiting |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Hatim Husain |
| Enrollment | 30 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Advanced NSCLC |
| Drugs | Ipilimumab, Nivolumab and Oxaliplatin |
| Start | 14 Aug 2019 |
| Primary completion | 31 Dec 2025 |
| Study completion | 31 Dec 2026 |
| Last update posted | 28 May 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Hatim Husain
University of California, San Diego
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc San Diego Moores Cancer Center
La Jolla
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04043195
Each answer restates registry values shown on this page.
What is NCT04043195?
NCT04043195 is a phase 1/2 interventional trial sponsored by Hatim Husain. It studies Ipilimumab, Nivolumab and Oxaliplatin in Advanced NSCLC.
Is NCT04043195 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT04043195?
The registry names Hatim Husain (principal investigator, University of California, San Diego) as the overall official.
Where does NCT04043195 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04043195 study?
The registered drug and biological interventions are Ipilimumab, Nivolumab and Oxaliplatin.
When is NCT04043195 expected to complete?
The registry lists a primary completion date of 31 Dec 2025 and a study completion date of 31 Dec 2026. The sponsor last updated the record on 28 May 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.